Helen M. Johnson
YOU?
Author Swipe
View article: ASO Author Reflections: Oncolactation Guidelines for Patients with Breast Cancer
ASO Author Reflections: Oncolactation Guidelines for Patients with Breast Cancer Open
View article: Oncolactation for Patients with Breast Cancer: Executive Summary from the American Society of Breast Surgeons
Oncolactation for Patients with Breast Cancer: Executive Summary from the American Society of Breast Surgeons Open
Despite increasing rates of pregnancy-related and postpartum breast cancers and growing recognition of oncofertility as an important component of survivorship, few guidelines exist to guide surgical oncologists in managing lactation during…
View article: Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma
Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma Open
View article: P173: Phase 2 trial of ablative radiotherapy and endocrine therapy for invasive breast cancer without surgery: patient reported outcomes
P173: Phase 2 trial of ablative radiotherapy and endocrine therapy for invasive breast cancer without surgery: patient reported outcomes Open
View article: Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy
Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy Open
Introduction Prior studies of patients treated for breast cancer during pregnancy (PrBC) report mixed outcomes and are limited by substandard treatment, small cohorts, and short follow‐up. This study compared survival outcomes of PrBC pati…
View article: Clinical Outcomes for <i>BRCA</i> Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation
Clinical Outcomes for <i>BRCA</i> Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation Open
Importance Although most women with BRCA- associated breast cancer choose bilateral mastectomy, current guidelines support breast-conserving therapy as an option. As the indications for genetic testing expand and targeted therapies emerge,…
View article: 243MO Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial
243MO Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial Open
View article: Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy Open
Importance Patients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials. Objective To evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfor…
View article: Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067 Open
View article: Parents and Children Reading Together: Expanding Shared Book-Reading Across Genres
Parents and Children Reading Together: Expanding Shared Book-Reading Across Genres Open
In this conceptual article we explore parents’ shared book reading (SBR) interactions with their preschoolers across different book genres in their natural home settings. We consider the unique and shared contributions of narrative, inform…
View article: Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma Open
Background Survival heterogeneity and limited trial follow-up present challenges for estimating lifetime benefits of oncology therapies. This study used CheckMate 067 (NCT01844505) extended follow-up data to assess the predictive accuracy …
View article: A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆ Open
Results of this MAIC demonstrated durable OS and PFS benefits for patients with BRAF-mutant advanced melanoma treated with NIVO+IPI compared with BRAF/MEK inhibitors, with the greatest benefits noted after 12 months.
View article: PCN105 Comparison of Healthcare Costs in France of Combination Nivolumab and Ipilimumab Treatment Versus Nivolumab Monotherapy and Ipilimumab Monotherapy in Advanced Melanoma
PCN105 Comparison of Healthcare Costs in France of Combination Nivolumab and Ipilimumab Treatment Versus Nivolumab Monotherapy and Ipilimumab Monotherapy in Advanced Melanoma Open
View article: Transformer les services de physiothérapie à l’ère de la COVID-19 : un appel à l’action pour la téléréadaptation
Transformer les services de physiothérapie à l’ère de la COVID-19 : un appel à l’action pour la téléréadaptation Open
L’émergence de la maladie à coronavirus 2019 (COVID-19) constitue une menace pour la santé mondiale et pose des défis à l’égard du mode de prestation des services de physiothérapie. Les physiothérapeutes ont l’obligation éthique non seulem…
View article: Transforming the Provision of Physiotherapy in the Time of COVID-19: A Call to Action for Telerehabilitation
Transforming the Provision of Physiotherapy in the Time of COVID-19: A Call to Action for Telerehabilitation Open
The emergence of coronavirus disease 2019 (COVID-19) has presented a global health threat, and it poses challenges to how physiotherapists deliver health care. Physiotherapists have an ethical obligation not only to reduce the spread of CO…
View article: Associations Between Career Satisfaction, Personal Life Factors, and Work-Life Integration Practices Among US Surgeons by Gender
Associations Between Career Satisfaction, Personal Life Factors, and Work-Life Integration Practices Among US Surgeons by Gender Open
IMPORTANCE: Burnout among US surgeons is alarmingly high, particularly among women, and work-life integration conflicts contribute to career dissatisfaction. OBJECTIVE: To evaluate associations between surgical career satisfaction and pers…
View article: PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067 Open
View article: PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE)
PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE) Open
View article: Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis
Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis Open
View article: Call to Action: Universal Policy to Support Residents and Fellows Who Are Breastfeeding
Call to Action: Universal Policy to Support Residents and Fellows Who Are Breastfeeding Open
Breastfeeding confers a multitude of health benefits to women and children, and it improves workplace productivity.1 The World Health Organization recommends exclusive breastfeeding for 6 months and continued breastfeeding combined with co…
View article: Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma Open
The total costs incurred by a patient over a 48-month period following treatment initiation with NIVO + IPI are lower when compared with patients initiating monotherapies; further, the cost advantage is seen to be increasing over time. The…
View article: ABM Clinical Protocol #30: Breast Masses, Breast Complaints, and Diagnostic Breast Imaging in the Lactating Woman
ABM Clinical Protocol #30: Breast Masses, Breast Complaints, and Diagnostic Breast Imaging in the Lactating Woman Open
A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols, free from commercial interest or influence, for managing common medical problems that may impact breastfeeding success. These protocols se…
View article: Esophageal perforation secondary to malignant gastric outlet obstruction: a case report
Esophageal perforation secondary to malignant gastric outlet obstruction: a case report Open
View article: The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study
The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study Open
Background. Inflammatory breast cancer (IBC) is a rare but most aggressive breast cancer subtype. The impact of locoregional therapy on survival in IBC is controversial. Methods. Patients with nonmetastatic IBC between 1988 and 2013 were i…
View article: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England Open
View article: The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England
The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England Open
Nivolumab is a cost-effective treatment for advanced melanoma patients in England.
View article: Pseudoangiomatous stromal hyperplasia presenting as accessory axillary breast tissue.
Pseudoangiomatous stromal hyperplasia presenting as accessory axillary breast tissue. Open